Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | TGM2 | P21980 | 8/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | DDO | Q99489 | 1/20 | 0.44 |
| ▸ | F13A1 | P00488 | 1/20 | 0.42 |
| ▸ | TGM1 | P22735 | 1/20 | 0.42 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.42 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL503852 | 0.80 | TGM2 (0.57) | TGM2MEN1KMT2ALMNAPOLB | |
| SCHEMBL7776267 | 0.80 | TGM2 (0.57) | ALDH1A1TGM2MEN1KMT2ALMNA | |
| SCHEMBL24568741 | 0.78 | TGM2 (0.58) | ALDH1A1TGM2HCAR2MEN1KMT2A | |
| SCHEMBL16097290 | 0.78 | TGM2 (0.46) | KDM4EALDH1A1TGM2MEN1KMT2A | |
| SCHEMBL31015916 | 0.77 | KDM4E (0.68) | KDM4EALDH1A1HCAR2MEN1KMT2A | |
| SCHEMBL22139456 | 0.77 | ALDH1A1 (0.62) | KDM4EALDH1A1HCAR2MEN1KMT2A | |
| SCHEMBL185842 | 0.77 | KDM4E (0.68) | KDM4EALDH1A1HCAR2MEN1KMT2A | |
| SCHEMBL16918471 | 0.75 | ALDH1A1 (0.59) | KDM4EALDH1A1HCAR2MEN1KMT2A | |
| SCHEMBL1668968 | 0.75 | TGM2 (0.65) | TGM2MEN1KMT2ALMNA | |
| SCHEMBL15456304 | 0.75 | ALDH1A1 (0.59) | KDM4EALDH1A1HCAR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3684776-B1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | UNIV NOTTINGHAM (GB) | 2023-11-01 | — | — | EP | disclosed |
| US-11407767-B2 | Heterocyclyl substituted pyrrolopyridines that are inhibitors of the CDK12 kinase | UNIV NOTTINGHAM (GB) | 2022-08-09 | — | — | US | disclosed |
| US-20200247824-A1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | THE UNIVERSITY OF NOTTINGHAM (GB) | 2020-08-06 | — | — | US | disclosed |
| EP-3684776-A1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | The University of Nottingham (GB) | 2020-07-29 | — | — | EP | disclosed |
| WO-2019058132-A1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | THE UNIVERSITY OF NOTTINGHAM (GB) | 2019-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247824-A1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | CDK1, CDK11A, CDK12 | KDM4E 1068/4885ALDH1A1 4568/4885TGM2 3151/4885 |
| US-11407767-B2 | Heterocyclyl substituted pyrrolopyridines that are inhibitors of the CDK12 kinase | CDK1, CDK11A, CDK12 | KDM4E 1068/4885ALDH1A1 4568/4885TGM2 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.